Tech Center 1600 • Art Units: 1624
This examiner grants 88% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18344405 | Azetidinyl Pyrimidines and Uses Thereof | Non-Final OA | Alcon Inc. |
| 18043389 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR CONTAINING SUBSTITUENTS | Final Rejection | SYNGENTA CROP PROTECTION AG |
| 18564384 | CANCER THERAPY USING A COMBINATION OF CDK7 INHIBITOR WITH AN ANTI-CANCER AGENT | Non-Final OA | Aurigene Oncology Limited |
| 17928858 | 1,2,4-TRIOXANE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME FOR USE IN THE PREVENTION AND TREATMENT OF CANCER | Non-Final OA | University of Kentucky Research Foundation |
| 18258989 | THERAPY BASED ON SYNTHETIC LETHALITY IN SWI/SNF COMPLEX-DYSFUNCTION CANCER | Non-Final OA | Sumitomo Pharma Co., Ltd. |
| 18270613 | METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY | Non-Final OA | Duke University |
| 17919768 | STABILIZED COSMETIC COMPOSITIONS WITH N, N'-DI-ACETYL CYSTINE | Non-Final OA | Conopco, Inc., d/b/a UNILEVER |
| 18275692 | SIGMA RECEPTOR LIGANDS FOR TREATING SARS-COV-2 INFECTION | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18269073 | IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS IRAK4 INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE | Non-Final OA | BIOGEN MA INC. |
| 18042920 | TREATMENT AND/OR PREVENTION OF A VIRAL INFECTION | Non-Final OA | Aslan Pharmaceuticals PTE LTD |
| 17909941 | CERAMIDE GROWTH PROMOTING AGENT | Final Rejection | TAKASAGO INTERNATIONAL CORPORATION |
| 18033055 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Non-Final OA | Azura Ophthalmics Ltd. |
| 18572867 | EGFR INHIBITORS | Non-Final OA | Blueprint Medicines Corporation |
| 18259458 | CANNABINOIDS AND USES THEREOF FOR TREATMENT OF ESTROGEN RECEPTOR RELATED DISEASES | Final Rejection | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LIMITED |
| 18568840 | Heteroaryl compounds as inhibitors of TYK2, composition and application thereof | Non-Final OA | Accro Bioscience (HK) Limited |
| 18028960 | A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF | Non-Final OA | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd |
| 18367631 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | Non-Final OA | Opus Genetics, Inc. |
| 18485224 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Non-Final OA | Maze Therapeutics, Inc. |
| 18285807 | METHODS OF TREATING METHYLMALONIC ACIDEMIA AND PROPIONIC ACIDEMIA | Non-Final OA | HemoShear Therapeutics, Inc. |
| 18549968 | TREATMENT METHOD FOR INTERSTITIAL PNEUMONIA | Non-Final OA | Shenzhen Evergreen Therapeutics Co., Ltd |
| 18263318 | CRYSTALLINE FORM OF A PIPERAZINYL-THIAZOLE DERIVATIVE | Non-Final OA | Idorsia Pharmaceuticals Ltd |
| 18453549 | COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION OF COMPOUND IN PREPARATION OF BICYCLOPYRONE INTERMEDIATE | Non-Final OA | SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD |
| 18273634 | PHOSPHOINOSITIDE 3 KINASE BETA INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Non-Final OA | XtalPi, Inc. |
| 18262319 | ANTI-SENESCENCE PLANT POLYPHENOL DRUG DOWNREGULATING SENESCENCE-RELATED SECRETORY PHENOTYPE AND USE THEREOF | Non-Final OA | BYHEALTH CO., LTD. |
| 17909162 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | Non-Final OA | CENTESSA PHARMACEUTICALS (UK) LIMITED |
| 18258857 | DEVELOPMENT OF AN INNOVATIVE INHALATION FORMULATION OF NAFAMOSTAT MESYLATE FOR THE MANAGEMENT OF COVID-19 | Non-Final OA | MEFAR ILAC SAN. A.S. |
| 18257801 | A JMJD6 TARGETING AGENT FOR TREATING PROSTATE CANCER | Non-Final OA | The United States Government represented by The Department Of Veterans Affairs |
| 18257541 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN-MLL INTERACTION | Non-Final OA | Biomea Fusion, Inc. |
| 18035770 | Heterocyclic Compound and Preparation Method and Use Thereof | Non-Final OA | SYNTRON (JIANGSU) PHARMACEUTICAL TECHNOLOGY CO., LTD. |
| 17918017 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | Non-Final OA | Malcolm Robert BATES |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy